EydisBio

Executive Summary

EydisBio is a private, early-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing selective TAK1 (transforming growth factor-β-activated kinase 1) inhibitors for autoimmune and inflammatory diseases. Founded in 2020, the company leverages its expertise in protein kinase inhibition to address significant unmet medical needs in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. TAK1 is a central node in multiple inflammatory signaling pathways, and its selective inhibition offers the potential for improved efficacy and reduced side effects compared to broad immunosuppressive therapies. EydisBio’s approach aims to harness the therapeutic benefits of TAK1 blockade while minimizing off-target toxicity, which has been a challenge for earlier kinase inhibitors. While the company remains in preclinical stages, its differentiated strategy and focus on high-value autoimmune indications position it as a promising player in the inflammation therapeutics landscape. Continued progress in lead optimization and IND-enabling studies will be critical for advancing toward clinical development and attracting partnership or investment interest.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-enabling studies and potential IND filing40% success
• Q3 2026Series A financing to support preclinical development60% success
• TBDAnnouncement of a strategic partnership or licensing deal for TAK1 program30% success